Essential Planning LLC. Invests $4.44 Million in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Essential Planning LLC. bought a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 413,088 shares of the biotechnology company’s stock, valued at approximately $4,437,000.

A number of other large investors have also modified their holdings of AVXL. JPMorgan Chase & Co. increased its stake in Anavex Life Sciences by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 1,191 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Anavex Life Sciences by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 1,671 shares in the last quarter. Foster Victor Wealth Advisors LLC increased its stake in Anavex Life Sciences by 5.6% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 2,000 shares in the last quarter. Opus Capital Group LLC increased its stake in Anavex Life Sciences by 6.1% in the 4th quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company’s stock valued at $373,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Nwam LLC increased its stake in Anavex Life Sciences by 0.3% in the 4th quarter. Nwam LLC now owns 913,051 shares of the biotechnology company’s stock valued at $9,806,000 after purchasing an additional 2,575 shares in the last quarter. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Stock Performance

Anavex Life Sciences stock opened at $8.90 on Thursday. The stock has a fifty day moving average of $9.48 and a two-hundred day moving average of $7.99. The company has a market capitalization of $757.07 million, a price-to-earnings ratio of -16.18 and a beta of 0.94. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, analysts forecast that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, February 18th. D. Boral Capital reissued a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.